Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas Sells 783 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 783 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $22,472.10. Following the completion of the sale, the chief accounting officer now owns 37,358 shares in the company, valued at approximately $1,072,174.60. This trade represents a 2.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Apellis Pharmaceuticals Stock Performance

APLS stock opened at $27.69 on Wednesday. The firm has a 50 day simple moving average of $31.86 and a 200 day simple moving average of $33.48. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90. The stock has a market cap of $3.44 billion, a P/E ratio of -13.64 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. During the same period last year, the business earned ($1.17) EPS. The company’s quarterly revenue was up 78.3% on a year-over-year basis. Research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Morgan Stanley started coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price on the stock. Oppenheimer cut their price objective on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Citigroup reduced their price objective on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Piper Sandler cut their target price on Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $46.65.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. Rhumbline Advisers raised its stake in shares of Apellis Pharmaceuticals by 2.2% during the 2nd quarter. Rhumbline Advisers now owns 123,565 shares of the company’s stock worth $4,740,000 after purchasing an additional 2,644 shares in the last quarter. State of New Jersey Common Pension Fund D raised its position in Apellis Pharmaceuticals by 6.6% during the second quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock valued at $1,735,000 after acquiring an additional 2,820 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in Apellis Pharmaceuticals by 46.7% during the second quarter. Oppenheimer Asset Management Inc. now owns 12,754 shares of the company’s stock valued at $489,000 after acquiring an additional 4,060 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Apellis Pharmaceuticals by 42.2% in the second quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock worth $5,161,000 after acquiring an additional 39,931 shares in the last quarter. Finally, Edgestream Partners L.P. increased its stake in shares of Apellis Pharmaceuticals by 240.4% during the 2nd quarter. Edgestream Partners L.P. now owns 54,572 shares of the company’s stock worth $2,093,000 after purchasing an additional 38,541 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).